Estimating the healthcare burden of Prurigo Nodularis in England: a CPRD database study

Figures & data

Figure 1. Study period.

Table 1. Demographic characteristics in patients with PN and patients with moderate-to-severe PN versus patients with mild PN.

Demographic	Patients with PN (N = 8,933)	Patients with MiPN (N = 2,462)	Patients with MSPN (N = 2,462)	p-value
Female, n (%)	5,114 (57%)	1,555 (63%)	1,555 (63%)	1
Age, years, mean (SD)	61 (17)	61 (15)	61 (15)	1
BMI, mean (SD)	30 (7)	29 (6)	31 (7)	<0.001
BMI Category, n (%)				<0.001
Underweight	72 (0.8%)	11 (0.4%)	22 (0.9%)
Normal	1,034 (12%)	260 (11%)	268 (11%)
Overweight	1,401 (16%)	412 (17%)	408 (17%)
Obese	1,014 (11%)	263 (11%)	366 (15%)
Severely Obese	478 (5.4%)	101 (4.1%)	190 (7.7%)
Very Severely Obese	326 (3.6%)	64 (2.6%)	162 (6.6%)
Missing	4,608 (52%)	1,351 (55%)	1,046 (42%)
Charlson Comorbidity Index, mean (SD)	1.73 (1.89)	1.48 (1.68)	2.36 (2.09)	<0.001

SD: Standard deviation, BMI: Body Mass Index.

Table 2. Prior conditions in patients with PN and patients with moderate-to-severe PN versus patients with mild PN.

Prior Condition n (%)	Patients with PN (N = 8,933)	Patients with MiPN (N = 2,462)	Patients with MSPN (N = 2,462)	p-value
Kidney Dialysis	240 (2.7%)	36 (1.5%)	151 (6.1%)	<0.001
Kidney Transplant	80 (0.9%)	5 (0.2%)	63 (2.6%)	<0.001
Hay fever	1,102 (12%)	294 (12%)	379 (15%)	<0.001
Peanut Allergy	169 (1.9%)	43 (1.7%)	90 (3.7%)	<0.001
Atopic Dermatitis	3,486 (39%)	875 (36%)	1,122 (46%)	<0.001
Chronic rhinosinusitis	74 (0.8%)	16 (0.6%)	32 (1.3%)	0.020
Asthma	2,911 (33%)	709 (29%)	1,095 (44%)	<0.001
Spontaneous Urticaria	<5	0 (0%)	<5	0.500
Eosinophilic Oesophagitis	257 (2.9%)	61 (2.5%)	109 (4.4%)	<0.001
COPD	1,052 (12%)	220 (8.9%)	432 (18%)	<0.001
Bullous Pemphioid	34 (0.4%)	<5	35 (1.4%)	<0.001
Liver Disease	959 (11%)	210 (8.5%)	470 (19%)	<0.001
HIV	142 (1.6%)	43 (1.7%)	41 (1.7%)	0.800
CKD	1,392 (16%)	316 (13%)	513 (21%)	<0.001

COPD: Chronic obstructive pulmonary disease, HIV: Human immunodeficiency virus, CKD: Chronic kidney disease.

Table 3. Healthcare resource use (rate of visits (PPY)) in patients with PN and patients with moderate-to-severe PN versus patients with mild PN.

	Rate of visits (PPY)			aIRR	P-value
	Patients with PN	Patients with MiPN	Patients with MSPN
All Patients
PC Contacts (any)	14.27	11.35	21.27	1.39	<0.0001
HES outpatient (any)	6.68	4.87	10.72	1.57	<0.0001
HES outpatient (dermatology)	1.76	1.14	1.96	1.16	<0.0001
HES inpatient (any)	1.07	0.66	1.75	1.28	<0.0001
HES inpatient (dermatology)	0.04	0.01	0.04	2.41	<0.0001
Patients with at least one visit to outpatient dermatology
PC Contacts (any)	15.31	12.15	22.12	1.32	<0.0001
HES outpatient (any)	8.89	6.27	12.85	1.51	<0.0001
HES outpatient (dermatology)	3.20	2.22	3.52	1.16	<0.0001
HES inpatient (any)	1.33	0.73	1.97	1.32	<0.0001
HES inpatient (dermatology)	0.07	0.02	0.07	2.41	<0.0001

PC: Primary care, HES: Hopsital episode statistics, aIRR: adjusted incidence rate ratio. The GLM’s adjusted for disease severity, BMI categories, Charlson Comorbidity Index, prior conditions and prior treatments.

Table 4. Cost (£PPY) of patients with PN and patients with moderate-to-severe PN versus patients with mild PN.

	Rate of costs (£ PPY)			aCRR	P-value
	Patients with PN	Patients with MiPN	Patients with MSPN
All Patients
PC Contacts (any)	359	274	537	1.55	<0.0001
HES outpatient (any)	755	563	1,213	1.62	<0.0001
HES outpatient (dermatology)	165	111	180	1.63	<0.0001
HES inpatient (any)	286	192	382	1.74	<0.0001
HES inpatient (dermatology)	31	8	34	4.12	<0.0001
Patients with at least one visit to outpatient dermatology
PC Contacts (any)	382	296	551	1.51	<0.0001
HES outpatient (any)	979	707	1,421	1.46	<0.0001
HES outpatient (dermatology)	298	216	324	1.07	0.4460
HES inpatient (any)	290	194	383	1.67	<0.0001
HES inpatient (dermatology)	55	16	61	3.40*	0.0002

PC: Primary care, HES: Hopsital episode statistics, aCRR: adjusted cost rate ratio.

*The following were removed from the HES inpatient (dermatology) model: BMI, Charlson Comorbidity index, prior peanut allergy, prior atopic dermatitis, prior asthma, prior eosinophilic oesophagitis, prior COPD, prior bullous pemphigoid, prior liver disease, prior topical calcineurin inhibitor, prior tricyclic antidepressant, prior first generation antihistamine, prior second generation antihistamine, prior gabapentinoids, prior corticosteroids. The GLM’s adjusted for disease severity, BMI categories, Charlson Comorbidity Index, prior conditions and prior treatments.

Data availability statement

The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.